Osteosarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Osteosarcoma – Pipeline Review, H1 2017’, provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteosarcoma

– The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects

– The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advaxis Inc

Allosteros Therapeutics Inc

Amgen Inc

AVEO Pharmaceuticals Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

CorMedix Inc

CytRx Corp

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Intezyne Technologies Inc

Isofol Medical AB

Johnson & Johnson

MacroGenics Inc

MD Biosciences GmbH

MediaPharma srl

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Novartis AG

Oncolys BioPharma Inc

Pfizer Inc

Shionogi & Co Ltd

Teijin Pharma Ltd

United Therapeutics Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Osteosarcoma Overview 7

Osteosarcoma Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Osteosarcoma Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 19

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Osteosarcoma Companies Involved in Therapeutics Development 26

Advaxis Inc 26

Allosteros Therapeutics Inc 26

Amgen Inc 27

AVEO Pharmaceuticals Inc 27

Bayer AG 28

Bellicum Pharmaceuticals Inc 28

Bristol-Myers Squibb Company 29

Celldex Therapeutics Inc 29

CorMedix Inc 30

CytRx Corp 30

Eisai Co Ltd 31

Eleison Pharmaceuticals LLC 31

Intezyne Technologies Inc 32

Isofol Medical AB 32

Johnson & Johnson 33

MacroGenics Inc 33

MD Biosciences GmbH 34

MediaPharma srl 34

Merck & Co Inc 35

Merck KGaA 35

Merrimack Pharmaceuticals Inc 36

Novartis AG 36

Oncolys BioPharma Inc 37

Pfizer Inc 37

Shionogi & Co Ltd 38

Teijin Pharma Ltd 38

United Therapeutics Corp 39

Osteosarcoma Drug Profiles 40

3D-QM Drug Profile 40

3D-QMS Drug Profile 41

ADXS-HER2 Drug Profile 42

aldoxorubicin hydrochloride Drug Profile 46

AM-7209 Drug Profile 63

AU-101 Drug Profile 64

AV-203 Drug Profile 65

avelumab Drug Profile 68

axitinib Drug Profile 77

Cellular Immunotherapy for GD2 Expressing Solid Tumors Drug Profile 83

Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma Drug Profile 85

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile 86

Celyvir Drug Profile 87

cisplatin SR Drug Profile 88

daunorubicin hydrochloride Drug Profile 90

dihydroartemisinin Drug Profile 91

dinutuximab Drug Profile 92

enoblituzumab Drug Profile 94

everolimus Drug Profile 97

glembatumumab vedotin Drug Profile 111

ipilimumab + nivolumab Drug Profile 116

irinotecan hydrochloride Drug Profile 120

IT-139 Drug Profile 132

JNJ-64457107 Drug Profile 134

lenvatinib mesylate Drug Profile 136

ligerin Drug Profile 149

MD-401A Drug Profile 150

Modufolin Drug Profile 151

Monoclonal Antibody for Osteosarcoma Drug Profile 153

Monoclonal Antibody to Inhibit GD2 for Oncology Drug Profile 154

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma Drug Profile 155

MPE-8.3 Drug Profile 157

NT-157 Drug Profile 158

OBP-702 Drug Profile 160

Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer Drug Profile 161

pazopanib hydrochloride Drug Profile 162

pembrolizumab Drug Profile 171

Peptide to Target COX-2 and MAS-GPCR for Oncology Drug Profile 219

radium Ra 223 dichloride Drug Profile 221

RSF-101 Drug Profile 230

S-588410 Drug Profile 232

SEN-461 Drug Profile 234

Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma Drug Profile 235

Small Molecules to Inhibit CaMKII for Osteosarcoma Drug Profile 236

taurolidine Drug Profile 237

Vaccine for Osteosarcoma Drug Profile 238

VIMO-001 Drug Profile 239

Osteosarcoma Dormant Projects 240

Osteosarcoma Discontinued Products 241

Osteosarcoma Product Development Milestones 242

Featured News & Press Releases 242

Appendix 250

Methodology 250

Coverage 250

Secondary Research 250

Primary Research 250

Expert Panel Validation 250

Contact Us 250

Disclaimer 251

List of Tables

List of Tables

Number of Products under Development for Osteosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Osteosarcoma Pipeline by Advaxis Inc, H1 2017

Osteosarcoma Pipeline by Allosteros Therapeutics Inc, H1 2017

Osteosarcoma Pipeline by Amgen Inc, H1 2017

Osteosarcoma Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Osteosarcoma Pipeline by Bayer AG, H1 2017

Osteosarcoma Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Osteosarcoma Pipeline by Bristol-Myers Squibb Company, H1 2017

Osteosarcoma Pipeline by Celldex Therapeutics Inc, H1 2017

Osteosarcoma Pipeline by CorMedix Inc, H1 2017

Osteosarcoma Pipeline by CytRx Corp, H1 2017

Osteosarcoma Pipeline by Eisai Co Ltd, H1 2017

Osteosarcoma Pipeline by Eleison Pharmaceuticals LLC, H1 2017

Osteosarcoma Pipeline by Intezyne Technologies Inc, H1 2017

Osteosarcoma Pipeline by Isofol Medical AB, H1 2017

Osteosarcoma Pipeline by Johnson & Johnson, H1 2017

Osteosarcoma Pipeline by MacroGenics Inc, H1 2017

Osteosarcoma Pipeline by MD Biosciences GmbH, H1 2017

Osteosarcoma Pipeline by MediaPharma srl, H1 2017

Osteosarcoma Pipeline by Merck & Co Inc, H1 2017

Osteosarcoma Pipeline by Merck KGaA, H1 2017

Osteosarcoma Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Osteosarcoma Pipeline by Novartis AG, H1 2017

Osteosarcoma Pipeline by Oncolys BioPharma Inc, H1 2017

Osteosarcoma Pipeline by Pfizer Inc, H1 2017

Osteosarcoma Pipeline by Shionogi & Co Ltd, H1 2017

Osteosarcoma Pipeline by Teijin Pharma Ltd, H1 2017

Osteosarcoma Pipeline by United Therapeutics Corp, H1 2017

Osteosarcoma Dormant Projects, H1 2017

Osteosarcoma Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Osteosarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports